共查询到19条相似文献,搜索用时 218 毫秒
1.
目的:选择适当辅料制备桑黄(裂蹄木层孔菌)多糖片剂,考察桑黄总多糖溶出度。方法:正交设计法优选处方,以PPVP为崩解剂、CaHPO4为填充剂、1%的PVP乙醇溶液为黏合剂、硬脂酸镁和微粉硅胶为润滑剂制备桑黄多糖片剂;采用紫外分光光度法以桑黄总多糖含量为测定指标,考察其溶出度。结果与结论:按最佳工艺制备的桑黄多糖片剂,溶出度良好,符合药典要求。 相似文献
2.
3.
复方羟氨苄头孢菌素分散片的研制及溶出度考察 总被引:1,自引:0,他引:1
目的:制备复方羟氨苄头孢菌素分散片并考察其体外溶出度。方法:以微晶纤维素为填充剂,聚乙烯聚吡咯烷酮为崩解剂,湿法制粒法制备分解片。以转篮法考察制剂的体外溶出度,测定样品的崩解时间和分散质量。用HPLC法测定药物含量。结果:样品质量稳定合格,崩解时间小于2min,药物累积溶出百分率在20min内均可达90%。结论:该制剂处方合理,制备工艺简单,值得推广。 相似文献
4.
5.
6.
目的:制备以卡波姆(Cb)为阻滞剂的红霉素缓释栓并研究其处方组成、制备工艺。方法:以PEG6000、PEG400为基质,加入生物粘附材料卡波姆制成红霉素缓释栓,采用紫外分光光度法测定红露素缓释栓中红霉素的含量及溶出度。结果:在1h以前的溶出动力学过程接近0级速度过程,普通栓2h溶出91.21%,5h溶出95.92%。缓释栓B 2h溶出76.26%,5h溶出94.02%。缓释栓C 2h溶出69.70%,5h溶出89.60%。缓释栓C的体外释放优于单独以Cb作缓释剂的缓释栓B。结论:与普通红霉素栓剂相比,采用粘附材料卡波姆作缓释剂可以有效地控制栓剂中药物的释放速率。 相似文献
7.
8.
9.
10.
目的利用六通道光纤药物溶出度测定仪,建立实时、在位监测格列齐特片Ⅱ体外溶出度的测定方法,并比较测定不同厂家共7批格列齐特片Ⅱ的体外溶出参数。方法采用FODT-601检测了格列齐特片Ⅱ的溶出度,并与《中国药典》药品标准溶出度测定结果进行了比较,无显著性差异(P〉0.05)。溶出度测定条件为:测定波长240nm、基线校正波长290nm、温度37℃、转速150r!min、数据采集间隔120s、监测时间180min、溶出介质为磷酸盐缓冲液pH(8.60±0.05)、溶出体积1000ml、转篮法、光纤探头2mm。结果共测定了两个厂家不同批次的格列齐特片Ⅱ在60、180min的溶出度及溶出曲线,其中一个厂家的格列齐特片Ⅱ符合《中国药典》规定,另一个厂家的格列齐特片Ⅱ在180min的溶出度不符合《中国药典》规定。两个厂家的格列齐特片Ⅱ溶出曲线存在非常显著性差异。结论光纤药物溶出度实时测定仪原位、准确、连续、定量地反映了药物的溶出过程,可比较出不同厂家之间同种药品的溶出过程差异。 相似文献
11.
Jovanović D Kilibarda V Todorović V Potrebić O 《Vojnosanitetski pregled. Military-medical and pharmaceutical review》2005,62(12):887-893
BACKGROUND/AIM: Switching the patient from one pharmaceutical formulation of the same drug to another, may lead to therapeutic inadequancy in some cases. To minimize the risk, careful pharmacokinetic studies are desired in the pre-registration period and afterwards. METHODS: A randomized, crossover design with one-week wash-out period between each dose was applied. Serum samples, obtained before dosing and at various appropriate time points up to 15 hours, were analyzed for nimesulide content by a high-performance liquid chromatographic method with ultraviolet (LU) detection. The pharmacokinetics and relative bioavailability of three different pharmaceutical formulations containing nimesulide, manufactured by the same pharmaceutical factory, were studied prospectively in 12 healthy subjects of both sexes. A single 100-mg oral dose of nimesulide was given to the volunteers in the form of conventional tablets, mouth dissolving tablets or as a suspension. Analysis of variance, power analysis, 90% confidence intervals, and two one-sided tests were used for the statistical analysis of pharmacokinetic parameters. RESULTS: The tolerability of all preparations was excellent. The respective confidence intervals of the ratios of geometric means of C(max) and AUC(0-infinity) of nimesulide were out of acceptable limits either for conventional tablets in comparison with suspension or for mouth dissolving tablets when compared with conventional tablets. A comparison of mouth dissolving tablets with suspension showed a statistically significant difference between C(max) values (suprabioavailability of mouth dissolving tablets), while the point estimate of the ratio of geometric means of AUC(0-infinity) was 0.945 with the corresponding 90% confidence interval of 0.902-0.991. At the 5% level of significance, there were no differences between the formulations under the study in times elapsed to peak serum concentrations, as revealed by the non-parametric Wilcoxon signed ranks test. CONCLUSION: Only a 90% confidence interval for the relative differences of log-transformed AUC(0-infinity) values of nimesulide absorbed from mouth dissolving tablets vs. suspension was included in the 80% to 125% interval proposed by the Food and Drug Administration (FDA). On that basis, mouth dissolving tablets (Nimulid-MD) were considered bioequivalent to Nimulid suspension according to the extent of drug absorption. Concerning the comparable amounts of nimesulide available in the systemic circulation after application of these formulations the one might not expect therapeutic failure after switching the patient from one to another. 相似文献
12.
13.
目的以MCC、PVPP和泡腾剂为崩解剂制备茶苯海明口腔崩解片。方法以聚丙烯酸树脂E100为载体制备茶苯海明包合物以掩蔽其苦麻味,采用粉末直接压片法制备片剂,运用星点设计-效应面法进行处方优化,并对药物体外溶出进行评估。结果以MCC、PVPP和泡腾剂含量为自变量,体外崩解时间为因变量进行二次多项式拟合,结果表明,拟合的效果较好,较优处方为MCC 5.3%、PVPP 8.1%、泡腾剂15.6%。与市售普通片比较,口腔崩解片具有明显速释效果。结论将茶苯海明制成口腔崩解片能显著提高其体外溶出速度。 相似文献
14.
萘普生缓释片体外释放与人体内吸收的相关性研究 总被引:1,自引:0,他引:1
目的研究萘普生缓释片体外释放与人体内吸收的相关性。方法按《中国药典》2005年版二部附录XD第一法,以0.05mol.L-1磷酸二氢钾缓冲液(pH7.4)为释放介质,采用紫外分光光度法测定萘普生缓释片累积溶出百分率(Fd);采用HPLC法测定健康志愿者口服萘普生缓释片后的血药浓度,用WagnerNelsion方程计算萘普生缓释片在人体内不同时间点的吸收百分数(Fa)。以Fd为自变量,Fa为因变量,进行直线回归,并进行体内-体外相关性检验。结果萘普生缓释片人体内不同时间点的吸收百分数Fa与体外累积溶出百分率Fd的线性回归方程为:Fa=1.384Fd+13.749,r=0.9631,P〈0.01。结论萘普生缓释片体内-体外相关性显著,体外释放度测定方法可有效控制萘普生缓释片内在质量和预测其生物利用度。 相似文献
15.
目的 测定1'-乙酰氧基胡椒酚乙酸酯片的溶出度.方法 采用高效液相色谱法测定含量,λmax=218nm,溶出度以小杯法测定,转速50 r/min,溶出介质为200 ml蒸馏水.结果 当1'-乙酰氧基胡椒酚乙酸酯浓度为10 -100 μg/ml时,浓度与峰面积线性关系良好,回归方程为:Y=21941X+9741.2,r2... 相似文献
16.
两种制粒方法制备口腔速溶片的工艺比较 总被引:2,自引:0,他引:2
目的制备盐酸羟考酮口腔速溶片,并初步探讨其速溶机理。方法分别采用流化床一步制粒法和手工湿法制粒两种工艺制备颗粒,比铰颗粒外观、流动性、粒径分布、孔隙结构的差异;颗粒压片后,比较所得片剂在崩解时间上的差异。结果以流动性指数为考察标准,发现采用流化床制得的颗粒均一性、可压缩性、流动性明显好于手工湿法颗粒,前者所得片剂的崩解时间明显快于后者。结论用流化床制粒可获得较为理想的盐酸羟考酮口腔速溶片,其高孔隙颗粒结构与其速溶机理密切相关。 相似文献
17.
维生素C缓释包衣片的研究 总被引:2,自引:1,他引:1
目的: 制备维生素C缓释包片,考察自制的渗透型丙烯酸树脂与Eudragit RS/RL的一致性及包衣片的稳定性。方法:分别以自制的渗透型丙烯酸树脂和标准样品为薄膜包衣材料,制备维生素C缓释包衣片,以体外溶出试验,考察二者的缓释性能及所得包衣缓释片的稳定性。结果:转蓝法测定药物溶出度表明,用Eudragit RL和RS包衣的缓释片,其释药速度有明显的差别,但在10h 内均以零级动力学过程连续释药;自制的RL和RS产品达到了国外同类产品的应用性能要求。结论:自制的渗透型缓释材料与标准样品EudragitRS/RL 基本一致;维生素C缓释包衣片能延缓药物氧化、增加片剂的稳定性 相似文献
18.
目的建立尼美舒利体外释放评价方法,并考察体内外相关性。方法采用转篮法,以pH 9.0的三羟甲基氨基甲烷缓冲液为释放介质,测定尼美舒利体外释放度;LC-MS/MS法测定犬体内血药浓度,应用Wagner-Nelson法评价尼美舒利双层缓释片体内外相关性。结果与结论测得的体外累计释放度(Y)与吸收分数(X)回归方程为:Y=2.683X-40.21(r=0.9618),表明尼美舒利双层缓释片体内外相关性良好。 相似文献